Dive performance in a small-bodied, semi-aquatic mammal in the wild

Aquatic foraging is a fundamental component of the behavior of a number of small mammals, yet comprehensive observations of diving are often difficult to obtain under natural circumstances. Semiaquatic mammals, having evolved to exploit prey in both aquatic and terrestrial environments, are generally not as well adapted for diving (or for life in the water) as are fully aquatic species. Because dive ability also tends to increase with body size, small, semiaquatic mammals are presumed to have fairly limited dive ability. Nevertheless, diving plays an important role in food acquisition for many such species. We used time–depth recorders (TDRs) to measure and describe the dive performance of 9 female and 5 male free-living American mink (Neovison vison; body mass approximately 1 kg) on lowland rivers in the southern United Kingdom. We recorded dives up to 2.96 m deep (maximum depth X ¯ 5 1.82 m) and up to 57.9 s in duration (maximum duration X ¯ 5 37.2 s). Dive duration was approximately 40% of that predicted by allometry for all air-breathing diving vertebrates (as might be expected for a small, semiaquatic animal) but was twice as long as previously measured for mink in captivity. Mink performed up to 189 dives per day (X ¯ 5 35.7 dives/day), mostly during daylight, and spent a maximum of 38.4 minutes diving per day (X ¯ 5 7.6 min/day). Some individuals maintained particularly high diving rates over the coldest months, suggesting that the benefits of aquatic foraging in winter outweigh the costs of heat loss. We observed a number of very shallow dives (depth approximately 0.3 m) of particularly long duration (up to 30 s). The function of these dives is currently unknown, but possibilities include searching for prey, travelling, or avoidance of threats. There is only 1 other study of which we are aware that presents detailed measurements of dive performance in a small, shallow-diving, semiaquatic mammal.Fil: Harrington, Lauren. University of Oxford; Reino UnidoFil: Hays, Graeme C.. Swansea University; Reino UnidoFil: Fasola, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Austral de Investigaciones Científicas; ArgentinaFil: Harrington, Andrew L.. University of Oxford; Reino UnidoFil: Righton, David. No especifíca;Fil: Macdonald, David W.. University of Oxford; Reino Unid

An experimental model of episodic gas release through fracture of fluid confined within a pressurized elastic reservoir

We present new experiments that identify a mechanism for episodic release of gas from a pressurized, deformable reservoir confined by a clay seal, as a result of the transition from bulk deformation to channel growth through the clay. Air is injected into the center of a thin cylindrical cell initially filled with a mixture of bentonite clay and water. For sufficiently dry mixtures, the pressure initially increases with little volume change. On reaching the yield stress of the clay‐water mixture, the lid of the cell then deforms elastically and an air‐filled void forms in the center of the cell as the clay is driven radially outward. With continued supply of air, the pressure continues to increase until reaching the fracture strength of the clay. A fracture‐like channel then forms and migrates to the outer edge of the cell, enabling the air to escape. The pressure then falls, and the clay flows back toward the center of the cell and seals the channel so the cycle can repeat. The phenomena may be relevant at mud volcanoes

New crystal packing arrangements in radical cation salts of BEDT-TTF with [Cr(NCS)6]3− and [Cr(NCS)5(NH3)]2−

BEDT-TTF forms three packing arrangement styles in its radical cation salts with [Cr(NCS)6]3− in two of which two trans-oriented isothiocyanate ligands penetrate the BEDT-TTF layers either at the point where a solvent (nitrobenzene) is incorporated in a stack of donors or by four donor molecules forming a “tube” motif to accept a ligand at each end along with a small solvent molecule in between (acetonitrile). The [Cr(NCS)5NH3]2− ion forms a related crystal packing arrangement with BEDT-TTF with a reduction in the number of “tube” motifs needed to accept an isothiocyanate ligand

Rensching cats and dogs: feeding ecology and fecundity trends explain variation in the allometry of sexual size dimorphism

The tendency for sexual size dimorphism (SSD) to increase with body mass in taxa where males are larger, and to decrease when females are larger, is known as Rensch's rule. In mammals, where the trend occurs, it is believed to be the result of a competitive advantage for larger males, while female mass is constrained by the energetics of reproduction. Here, we examine the allometry of SSD within the Felidae and Canidae, demonstrating distinctly different patterns: in felids, there is positive allometric scaling, while there is no trend in canids. We hypothesize that feeding ecology, via its effect on female spacing patterns, is responsible for the difference; larger male mass may be advantageous only where females are dispersed such that males can defend access to them. This is supported by the observation that felids are predominately solitary, and all are obligate carnivores. Similarly, carnivorous canids are more sexually dimorphic than insectivores and omnivores, but carnivory does not contribute to a Rensch effect as dietary variation occurs across the mass spectrum. The observed inter-familial differences are also consistent with reduced constraints on female mass in the canids, where litter size increases with body mass, versus no observable allometry in the felids

New chiral organosulfur donors related to bis(ethylenedithio)tetrathiafulvalene

Six new enantiopure chiral organosulfur donors, with structures related to BEDT-TTF, have been synthesised for use in the preparation of organic metals, starting either by double nucleophilic substitutions on the bis-mesylate of 2R,4Rpentane-2,4-diol or by a cycloaddition with subsequent elimination of acetic acid on the enol acetate of (+)-nopinone. Crystal structures of some of their radical cation triiodides salts and TCNQ complexes are reported

The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma

The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups. It was largely derived using clinical data from patients treated in the era that preceded the development of newer therapies such as BRAF, MEK and immune checkpoint inhibitors. Therefore, its current relevance to patients diagnosed with brain metastases from malignant melanoma is unclear. This study is an external validation of the msGPA in two temporally distinct British populations.Performance of the msGPA was assessed in Cohort I (1997-2008, n=231) and Cohort II (2008-2013, n=162) using Kaplan-Meier methods and Harrell's c-index of concordance. Cox regression was used to explore additional factors that may have prognostic relevance.The msGPA does not perform well as a prognostic score outside of the derivation cohort, with suboptimal statistical calibration and discrimination, particularly in those patients with an intermediate prognosis. Extra-cerebral metastases, leptomeningeal disease, age and potential use of novel targeted agents after brain metastases are diagnosed, should be incorporated into future prognostic models.An improved prognostic score is required to underpin high-quality randomised controlled trials in an area with a wide disparity in clinical care

Contrasting crystal packing arrangements in triiodide salts of radical cations of chiral bis(pyrrolo[3,4-d])tetrathiafulvalenes

Crystal structures of six 1 : 1 triiodide salts of a series of enantiopure bis(pyrrolo[3,4-d])TTF derivatives, the first structures of radical cation salts reported for this bis(pyrrolo) donor system, show three different arrangements of triiodide ions, organised either in head-to-tail pairs, in infinite lines, or in a castellated arrangement. The complex crystal structures, obtained by electrocrystallisation, are influenced by the presence of solvent, for example changing an ABCABC packing arrangement to ABAB with inclusion of THF, as well as by the size of the chiral side chain

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals - the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab - for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing. These consensus guidelines serve as a foundation to assist clinicians\u27 understanding of the role of immunotherapies in this disease setting, and to standardize utilization across the field for patient benefit. Due to country-specific variances in approvals, availability and regulations regarding the discussed agents, this panel focused solely on FDA-approved drugs for the treatment of patients in the U.S